文献速递骨软组织肉瘤与黑色素瘤

NRAS黑色素瘤中预存罕见PIK3CAE545K亚群导致MEK联合CDK4/6抑制获得性耐药且依赖S6K1信号

A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.
PubMed 文献 · Cancer Discov · 2018-03-01

本研究对一例初始对MEK抑制剂联合CDK4/6抑制剂(MEKi+CDK4i)治疗有反应后出现进展的NRAS突变黑色素瘤患者进行纵向活检分析。全外显子测序及功能验证发现获得性PIK3CAE545K突变导致耐药,该突变在治疗前以罕见亚群形式预存且分布不均,多区域采样才得以揭示。耐药亚群在治疗开始后迅速扩增,并在后续所有样本中持续存在;S6K1激活既是关键标志也是特异性治疗弱点。

要点

  • MEKi+CDK4i耐药的NRAS黑色素瘤中,预存PIK3CAE545K亚群在治疗后快速扩增并持续存在。
  • 单区域治疗前活检不足以检测罕见、空间分隔的耐药亚克隆。
  • 抑制S6K1可使表达PIK3CAE545K的NRAS突变黑色素瘤细胞对MEKi+CDK4i重新敏感。

核心结论

  • 预存PIK3CAE545K亚群可导致NRAS黑色素瘤对MEKi+CDK4i的临床获得性耐药,S6K1是其下游共同治疗节点。

研究设计与样本

  • 对一例初始对MEKi+CDK4i有反应后耐药的NRAS突变黑色素瘤患者进行纵向活检,行全外显子测序及功能验证。

主要发现

  • 全外显子测序和功能验证确定获得性PIK3CAE545K突变导致耐药。
  • PIK3CAE545K在治疗前以罕见亚群预存,临床和研究检测均漏检,多区域采样因分布不均而揭示。
  • 耐药亚群在MEKi+CDK4i治疗开始后迅速扩增,并在免疫检查点治疗和远处转移后的所有连续样本中持续存在。
  • 功能研究确定激活的S6K1既是PIK3CAE545K诱导耐药的关键标志,也是特异性治疗弱点。

关键数值与推荐

  • 抑制S6K1可使表达PIK3CAE545K的NRAS突变黑色素瘤细胞对MEKi+CDK4i重新敏感。

临床怎么用

  • 对NRAS黑色素瘤行MEKi+CDK4i治疗前应考虑多区域采样以检测罕见预存耐药亚群。
  • S6K1可作为克服PIK3CAE545K介导耐药的潜在治疗靶点。

局限性

  • 证据主要来自单例患者的纵向活检及功能研究,需更多临床样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Combined MEK and CDK4/6 inhibition (MEKi + CDK4i) has shown promising clinical outcomes in patients with NRAS-mutant melanoma. Here, we interrogated longitudinal biopsies from a patient who initially responded to MEKi + CDK4i therapy but subsequently developed resistance. Whole-exome sequencing and functional validation identified an acquired PIK3CAE545K mutation as conferring drug resistance. We demonstrate that PIK3CAE545K preexisted in a rare subpopulation that was missed by both clinical and research testing, but was revealed upon multiregion sampling due to PIK3CAE545K being nonuniformly distributed. This resistant population rapidly expanded after the initiation of MEKi + CDK4i therapy and persisted in all successive samples even after immune checkpoint therapy and distant metastasis. Functional studies identified activated S6K1 as both a key marker and specific therapeutic vulnerability downstream of PIK3CAE545K-induced resistance. These results demonstrate that difficult-to-detect preexisting resistance mutations may exist more often than previously appreciated and also posit S6K1 as a common downstream therapeutic nexus for the MAPK, CDK4/6, and PI3K pathways.Significance: We report the first characterization of clinical acquired resistance to MEKi + CDK4i, identifying a rare preexisting PIK3CAE545K subpopulation that expands upon therapy and exhibits drug resistance. We suggest that single-region pretreatment biopsy is insufficient to detect rare, spatially segregated drug-resistant subclones. Inhibition of S6K1 is able to resensitize PIK3CAE545K-expressing NRAS-mutant melanoma cells to MEKi + CDK4i. Cancer Discov; 8(5); 556-67. ©2018 AACR.See related commentary by Sullivan, p. 532See related article by Teh et al., p. 568This article is highlighted in the In This Issue feature, p. 517.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Romano G, Chen PL, Song P, et al. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018. PMID: 29496665. doi:10.1158/2159-8290.CD-17-0745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。